Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
Identifieur interne : 000184 ( PubMed/Curation ); précédent : 000183; suivant : 000185Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
Auteurs : Calvin J. Gordon [Canada] ; Egor P. Tchesnokov [Canada] ; Emma Woolner [Canada] ; Jason K. Perry [États-Unis] ; Joy Y. Feng [États-Unis] ; Danielle P. Porter [États-Unis] ; Matthias Gotte [Canada]Source :
- The Journal of biological chemistry [ 1083-351X ] ; 2020.
Abstract
Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Replication of SARS-CoV-2 depends on the viral RNA-dependent RNA polymerase (RdRp), which is the likely target of the investigational nucleotide analogue remdesivir (RDV). RDV shows broad-spectrum antiviral activity against RNA viruses, and previous studies with RdRps from Ebola virus (EBOV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have revealed that delayed chain-termination is RDV's plausible mechanism of action. Here, we expressed and purified active SARS-CoV-2 RdRp composed of the non-structural proteins nsp8 and nsp12. Enzyme kinetics indicated that this RdRp efficiently incorporates the active triphosphate form of RDV (RDV-TP) into RNA. Incorporation of RDV-TP at position i caused termination of RNA synthesis at position i+3. We obtained almost identical results with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRps. A unique property of RDV-TP is its high selectivity over incorporation of its natural nucleotide counterpart ATP. In this regard, the triphosphate forms of 2'-C-methylated compounds, including sofosbuvir, approved for the management of hepatitis C virus infection, and the broad-acting antivirals favipiravir and ribavirin, exhibited significant deficits. Furthermore, we provide evidence for the target specificity of RDV, as RDV-TP was less efficiently incorporated by the distantly related Lassa virus RdRp, and termination of RNA synthesis was not observed. These results collectively provide a unifying, refined mechanism of RDV-mediated RNA synthesis inhibition in coronaviruses and define this nucleotide analogue as a direct-acting antiviral (DAA).
DOI: 10.1074/jbc.RA120.013679
PubMed: 32284326
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000184
Links to Exploration step
pubmed:32284326Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.</title>
<author><name sortKey="Gordon, Calvin J" sort="Gordon, Calvin J" uniqKey="Gordon C" first="Calvin J" last="Gordon">Calvin J. Gordon</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Alberta</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Tchesnokov, Egor P" sort="Tchesnokov, Egor P" uniqKey="Tchesnokov E" first="Egor P" last="Tchesnokov">Egor P. Tchesnokov</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Alberta</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Woolner, Emma" sort="Woolner, Emma" uniqKey="Woolner E" first="Emma" last="Woolner">Emma Woolner</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Alberta</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Perry, Jason K" sort="Perry, Jason K" uniqKey="Perry J" first="Jason K" last="Perry">Jason K. Perry</name>
<affiliation wicri:level="1"><nlm:affiliation>Gilead Sciences, Inc, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Gilead Sciences, Inc</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Feng, Joy Y" sort="Feng, Joy Y" uniqKey="Feng J" first="Joy Y" last="Feng">Joy Y. Feng</name>
<affiliation wicri:level="1"><nlm:affiliation>Biology, Gilead Sciences, Inc., United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Biology, Gilead Sciences, Inc.</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Porter, Danielle P" sort="Porter, Danielle P" uniqKey="Porter D" first="Danielle P" last="Porter">Danielle P. Porter</name>
<affiliation wicri:level="1"><nlm:affiliation>Gilead Scienes, Inc., United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Gilead Scienes, Inc.</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gotte, Matthias" sort="Gotte, Matthias" uniqKey="Gotte M" first="Matthias" last="Gotte">Matthias Gotte</name>
<affiliation wicri:level="1"><nlm:affiliation>Medical Microbiology and Immunology, University of Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Medical Microbiology and Immunology, University of Alberta</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32284326</idno>
<idno type="pmid">32284326</idno>
<idno type="doi">10.1074/jbc.RA120.013679</idno>
<idno type="wicri:Area/PubMed/Corpus">000184</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000184</idno>
<idno type="wicri:Area/PubMed/Curation">000184</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000184</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.</title>
<author><name sortKey="Gordon, Calvin J" sort="Gordon, Calvin J" uniqKey="Gordon C" first="Calvin J" last="Gordon">Calvin J. Gordon</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Alberta</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Tchesnokov, Egor P" sort="Tchesnokov, Egor P" uniqKey="Tchesnokov E" first="Egor P" last="Tchesnokov">Egor P. Tchesnokov</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Alberta</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Woolner, Emma" sort="Woolner, Emma" uniqKey="Woolner E" first="Emma" last="Woolner">Emma Woolner</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Alberta</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Perry, Jason K" sort="Perry, Jason K" uniqKey="Perry J" first="Jason K" last="Perry">Jason K. Perry</name>
<affiliation wicri:level="1"><nlm:affiliation>Gilead Sciences, Inc, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Gilead Sciences, Inc</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Feng, Joy Y" sort="Feng, Joy Y" uniqKey="Feng J" first="Joy Y" last="Feng">Joy Y. Feng</name>
<affiliation wicri:level="1"><nlm:affiliation>Biology, Gilead Sciences, Inc., United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Biology, Gilead Sciences, Inc.</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Porter, Danielle P" sort="Porter, Danielle P" uniqKey="Porter D" first="Danielle P" last="Porter">Danielle P. Porter</name>
<affiliation wicri:level="1"><nlm:affiliation>Gilead Scienes, Inc., United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Gilead Scienes, Inc.</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gotte, Matthias" sort="Gotte, Matthias" uniqKey="Gotte M" first="Matthias" last="Gotte">Matthias Gotte</name>
<affiliation wicri:level="1"><nlm:affiliation>Medical Microbiology and Immunology, University of Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Medical Microbiology and Immunology, University of Alberta</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">The Journal of biological chemistry</title>
<idno type="eISSN">1083-351X</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Replication of SARS-CoV-2 depends on the viral RNA-dependent RNA polymerase (RdRp), which is the likely target of the investigational nucleotide analogue remdesivir (RDV). RDV shows broad-spectrum antiviral activity against RNA viruses, and previous studies with RdRps from Ebola virus (EBOV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have revealed that delayed chain-termination is RDV's plausible mechanism of action. Here, we expressed and purified active SARS-CoV-2 RdRp composed of the non-structural proteins nsp8 and nsp12. Enzyme kinetics indicated that this RdRp efficiently incorporates the active triphosphate form of RDV (RDV-TP) into RNA. Incorporation of RDV-TP at position i caused termination of RNA synthesis at position i+3. We obtained almost identical results with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRps. A unique property of RDV-TP is its high selectivity over incorporation of its natural nucleotide counterpart ATP. In this regard, the triphosphate forms of 2'-C-methylated compounds, including sofosbuvir, approved for the management of hepatitis C virus infection, and the broad-acting antivirals favipiravir and ribavirin, exhibited significant deficits. Furthermore, we provide evidence for the target specificity of RDV, as RDV-TP was less efficiently incorporated by the distantly related Lassa virus RdRp, and termination of RNA synthesis was not observed. These results collectively provide a unifying, refined mechanism of RDV-mediated RNA synthesis inhibition in coronaviruses and define this nucleotide analogue as a direct-acting antiviral (DAA).</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32284326</PMID>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN>
<JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year>
<Month>Apr</Month>
<Day>13</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of biological chemistry</Title>
<ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation>
</Journal>
<ArticleTitle>Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">jbc.RA120.013679</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.RA120.013679</ELocationID>
<Abstract><AbstractText>Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Replication of SARS-CoV-2 depends on the viral RNA-dependent RNA polymerase (RdRp), which is the likely target of the investigational nucleotide analogue remdesivir (RDV). RDV shows broad-spectrum antiviral activity against RNA viruses, and previous studies with RdRps from Ebola virus (EBOV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have revealed that delayed chain-termination is RDV's plausible mechanism of action. Here, we expressed and purified active SARS-CoV-2 RdRp composed of the non-structural proteins nsp8 and nsp12. Enzyme kinetics indicated that this RdRp efficiently incorporates the active triphosphate form of RDV (RDV-TP) into RNA. Incorporation of RDV-TP at position i caused termination of RNA synthesis at position i+3. We obtained almost identical results with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRps. A unique property of RDV-TP is its high selectivity over incorporation of its natural nucleotide counterpart ATP. In this regard, the triphosphate forms of 2'-C-methylated compounds, including sofosbuvir, approved for the management of hepatitis C virus infection, and the broad-acting antivirals favipiravir and ribavirin, exhibited significant deficits. Furthermore, we provide evidence for the target specificity of RDV, as RDV-TP was less efficiently incorporated by the distantly related Lassa virus RdRp, and termination of RNA synthesis was not observed. These results collectively provide a unifying, refined mechanism of RDV-mediated RNA synthesis inhibition in coronaviruses and define this nucleotide analogue as a direct-acting antiviral (DAA).</AbstractText>
<CopyrightInformation>Published under license by The American Society for Biochemistry and Molecular Biology, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gordon</LastName>
<ForeName>Calvin J</ForeName>
<Initials>CJ</Initials>
<AffiliationInfo><Affiliation>University of Alberta, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tchesnokov</LastName>
<ForeName>Egor P</ForeName>
<Initials>EP</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0003-1698-2961</Identifier>
<AffiliationInfo><Affiliation>University of Alberta, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Woolner</LastName>
<ForeName>Emma</ForeName>
<Initials>E</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-8697-7802</Identifier>
<AffiliationInfo><Affiliation>University of Alberta, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Perry</LastName>
<ForeName>Jason K</ForeName>
<Initials>JK</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0001-5492-0652</Identifier>
<AffiliationInfo><Affiliation>Gilead Sciences, Inc, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Feng</LastName>
<ForeName>Joy Y</ForeName>
<Initials>JY</Initials>
<AffiliationInfo><Affiliation>Biology, Gilead Sciences, Inc., United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Porter</LastName>
<ForeName>Danielle P</ForeName>
<Initials>DP</Initials>
<AffiliationInfo><Affiliation>Gilead Scienes, Inc., United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gotte</LastName>
<ForeName>Matthias</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Medical Microbiology and Immunology, University of Alberta, Canada.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Biol Chem</MedlineTA>
<NlmUniqueID>2985121R</NlmUniqueID>
<ISSNLinking>0021-9258</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">RNA polymerase</Keyword>
<Keyword MajorTopicYN="N">drug action</Keyword>
<Keyword MajorTopicYN="N">drug development</Keyword>
<Keyword MajorTopicYN="N">drug discovery</Keyword>
<Keyword MajorTopicYN="N">plus-stranded RNA virus</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>04</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>03</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>4</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32284326</ArticleId>
<ArticleId IdType="pii">RA120.013679</ArticleId>
<ArticleId IdType="doi">10.1074/jbc.RA120.013679</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000184 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000184 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:32284326 |texte= Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:32284326" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |